<DOC>
	<DOCNO>NCT02685657</DOCNO>
	<brief_summary>The purpose study increase survival patient early locally advanced triple-negative breast cancer add selumatinib standard preoperative chemotherapy regimen .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Docetaxel With Without SELUMETINIB Patients With Triple Negative Breast Cancer</brief_title>
	<detailed_description>Molecular analysis residual tumor administration neoadjuvant chemotherapy reveal several mechanism resistance treatment . High frequency RAS-RAF-MEK-ERK signal pathway activation find cell triple negative breast cancer neoadjuvant chemotherapy , correlate high proliferation index low pathological complete response rate . Thus , inhibition MEK molecule - intermediary transducer pathway may decrease activity pathway restore tumor sensitivity cytostatic agent . Hence , use SELUMETINIB , oral selective inhibitor MEK1/MEK2 kinases , combination Docetaxel increase pathological complete response rate turn increase survival patient early locally advanced triple-negative breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>• Written informed consent ; Women early locally advanced breast cancer ( Stage IIBIIIB : T2N12 , T34/N02 T/N2 ) Triple negative breast cancer ( absence estrogen receptor ( 02 point ) , progesterone receptor ( 02 point ) , HER2/neu receptor ( IHC 01+ IHC 2+ absence her2/neu gene amplification evidence FISH ) ; Age : 18 year ; Eastern Cooperative Oncology Group ( ECOG ) score : 01 point ; Left ventricular ejection fraction ( LVEF ) base Echocardiogram ( ECHO ) Multigated radionuclide angiography ( MUGA scan ) : &gt; 55 % Laboratory value study start must meet following criterion : Absolute neutrophil count &gt; 1500/microlitre Platelet count &gt; 100000/microlitre Hemoglobin level &gt; 9.0 g/dl Albumin &gt; 2,5 g/dl Normal plasma creatinine level estimate glomerular filtration rate ( eGFR ) &gt; 60 ml/minute Total bilirubin level &lt; 1.25 upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; 3 x ULN ; Patient able abide protocol requirement ( opinion Investigator ) Patient 's sexual partner 's willing use reliable method contraception ( condom spermicidal foams/gels , intrauterine device ) study least 4 week discontinuation study treatment . Negative serum pregnancy test woman childbearing potential evidence postmenopausal status ( total cessation menses 1 year . The follow agespecific requirement must also apply : Women &lt; 60 year old : would consider postmenopausal amenorrheic past 12 month . The level FollicleStimulating Hormone ( FSH ) estradiol must also postmenopausal range ( per institution ) . Women ≥ 60 year ; Bilateral oophorectomy . • Prior treatment ( chemo , hormone , radiation immunotherapy ) breast cancer Major surgery within 28 day prior enrollment ; Known hypersensitivity Docetaxel , SELUMETINIB components investigational product ; Cardiac condition follow : a. Uncontrolled hypertension ( BP ≥ 150/95 mmHg despite medical therapy ) b . Acute coronary syndrome within 6 month prior start treatment c. Uncontrolled Angina Canadian Cardiovascular Society grade IIIV despite medical therapy ( Appendix 3 ) d. Symptomatic heart failure New York Heart Association ( NYHA ) Class IIIV , prior current cardiomyopathy ( Appendix 4 ) e. Prior current cardiomyopathy include limited following : . Known hypertrophic cardiomyopathy ii . Known arrhythmogenic right ventricular cardiomyopathy iii . Previous moderate severe impairment leave ventricular systolic function ( Left ventricular ejection fraction ( LVEF ) &lt; 45 % echocardiography equivalent MuGA ) even full recovery occur . f. Severe valvular heart disease g. Baseline Left ventricular ejection fraction ( LVEF ) low limit normal ( LLN ) &lt; 55 % measure echocardiography institution 's LLN MUGA h. Atrial fibrillation ventricular rate &gt; 100 bpm ECG rest i. QTcF &gt; 450ms factor increase risk QT prolongation Pregnancy lactation ; Conditions ( dementia , psychiatric neurological disorder , drug addiction , alcoholism etc . ) limit patient 's ability undergo study procedure ; Simultaneous participation clinical study ; Presence acute active chronic infection condition ( e.g . unstable uncompensated respiratory , cardiac , hepatic , renal disease , active bleeding diatheses renal transplant ) , investigator 's opinion may interfere treatment describe study protocol ; Have refractory nausea vomiting , chronic gastrointestinal disease ( e.g. , inflammatory bowel disease ) , significant bowel resection would adversely affect absorption / bioavailability orally administer study medication History another neoplasm ( exception adequately treat basal cell cervical cancer situ case cancer remission 5 year ) Ophthalmological condition follow : Intraocular pressure &gt; 21 mmHg , uncontrolled glaucoma ( irrespective intraocular pressure ) Current past history retinal pigment epithelial detachment / central serous retinopathy Current past history retinal vein occlusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>